- Home
- HTD vs NBTX Comparison
HTD vs NBTX Comparison
Compare HTD & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HTD | NBTX |
|---|---|---|
| Founded | N/A | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 896.4M | 1.0B |
| IPO Year | 2003 | 2018 |
Fundamental Metrics
Financial Performance| Metric | HTD | NBTX |
|---|---|---|
| Price | $25.66 | $30.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $36.00 |
| AVG Volume (30 Days) | ★ 54.2K | 42.2K |
| Earning Date | 01-01-0001 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $59.10 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $21.47 | $3.12 |
| 52 Week High | $26.12 | $41.89 |
Technical Indicators
Market Signals| Indicator | HTD | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 62.17 | 49.09 |
| Support Level | $24.28 | $28.40 |
| Resistance Level | $25.65 | $34.66 |
| Average True Range (ATR) | 0.35 | 1.73 |
| MACD | 0.11 | -0.32 |
| Stochastic Oscillator | 94.70 | 31.59 |
Price Performance
Historical ComparisonAbout HTD John Hancock Tax Advantaged Dividend Income Fund of Beneficial Interest
John Hancock Tax-advantaged Div Inc Fd is a closed-end, diversified management investment company. Its investment objective is to provide a high after-tax total return from dividend income and capital appreciation. The fund's portfolio composition consists of common stocks, preferred securities, corporate bonds, convertible bonds, and short-term investments. Its sector composition comprises utilities, financials, energy, communication services, materials, healthcare, real estate, consumer Staples, and short-term investments.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.